Under one in 10 people eligible to benefit from obesity jabs like Wegovy are able to get them, warns the World Health Organization as it issues its first advice on the therapies.
Considering in excess of 1,000,000,000 people worldwide now obese, it is advocating for increased and just availability to this class of drugs.
Based on projections, over two billion are projected to be living with obesity by 2030 without intervention.
"The latest guidance acknowledges that excess weight is a lifelong illness that can be treated with comprehensive and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are significant obstacles to universal access to the treatments that can aid individuals in losing considerable body mass, explains the agency.
Weight-Loss Drug Supply Crisis
Despite the current most optimistic outlook, the supply of such drugs might only reach about 100 million people – under 10% of those who need them, according to the health organization.
The guideline calls on nations and manufacturers to expand availability, via approaches like voluntary licensing.
The intellectual property rights on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026.
How Obesity Injections Operate
These medications imitate a natural hormone to slow digestion, suppress the appetite and enhance satiety so users eat less.
People usually begin shedding pounds in the initial weeks of starting on the regular doses.
Studies indicates people may see weight return after a year of stopping the medication, because their usual hunger return.
To be carrying excess weight elevates your chance for experiencing health problems, such as diabetes, heart disease, stroke, and some malignancies.
Excess weight impacts people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, per the WHO.
